The Effect of MDR1 (ABCB1) Polymorphism on the Pharmacokinetic of Tacrolimus in Turkish Renal Transplant Recipients

Transplantation Proceedings

Volumn 38, Issue 5, 2006, Pages 1290-1292

  Akbas, S H ^a   Bilgen, T ^a   Keser, I ^a   Tuncer, M ^a   Yucetin, L ^a   Tosun, O ^a   Gultekin, M ^a   Luleci, G ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; IMMUNOSUPPRESSIVE AGENT; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ABCB1 GENE; ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENOTYPE; HOMOZYGOSITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PHARMACOGENETICS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; SINGLE NUCLEOTIDE POLYMORPHISM;

CREATININE; GENES, MDR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; METABOLIC CLEARANCE RATE; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; TACROLIMUS; TURKEY;

EID: 33745187536     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.02.079     Document Type: Article

References (11)

1. Hesselink D.A., van Schaik R.H., van der Heiden I.P., et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74 (2003) 245
2. Zhang Y., and Benet L.Z. The gut as a barrier to drug absorption. combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 40 (2001) 159
3. Tada H., Tsuchiya N., Satoh S., et al. Impact of CYP3A5 and MDR1 (ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc 37 (2005) 1730
4. Kelly P., and Kahan B.D. Review. metabolism of immunosuppressant drugs. Curr Drug Metab 3 (2002) 275
5. Anglicheau D., Verstuyft C., Laurent-Puig P., et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 14 (2003) 1889
6. Macphee I.A., Fredericks S., Tai T., et al. Tacrolimus pharmacogenetics. polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 74 (2002) 1486
7. Hoffmeyer S., Burk O., von Richter O., et al. Functional polymorphisms of the human multidrug-resistance gene. multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97 (2000) 3473
8. Zheng H., Webber S., Zeevi A., et al. The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum Immunol 63 (2002) 765
9. Haufroid V., Mourad M., Van Kerckhove V., et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14 (2004) 147
10. Mai I., Perloff E.S., Bauer S., et al. MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Br J Clin Pharmacol 58 (2004) 548
11. Tsuchia N., Satoh S., Tada H., et al. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 78 (2004) 1182